TABLE 3

Compounds showing effectiveness against HHV-6

DrugaProdrugChemical structureHHV-6 targetEC50b (μM)Clinical useReference(s)
GanciclovirValganciclovirNucleoside analogueDNA polymerase2.0–68.6Yes (approved for HCMV) 203, 204
FoscarnetNonePyrophosphate analogueDNA polymerase6–86Yes (approved for HCMV) 203, 204
CidofovirBrincidofovirNucleotide analogueDNA polymerase0.3–46Yes (approved for HCMV) 203, 204
H2GValomaciclovirNucleoside analogueDNA polymerase36.6Yes (clinical trials) 214 216
Cyclopropavir6-DeoxycyclopropavirNucleoside analogueDNA synthesis step0.5–7No (pharmaceutical development) 203, 204, 217 219
S2242NoneNucleoside analogueDNA polymerase0.02–0.03No (pharmaceutical development) 216, 220
3-Deaza-HPMPANoneNucleotide analogueDNA polymerase1.2–1.4No (discontinued development) 220
CMV423NoneIndolizinecarboxamideTyrosine kinasec 0.017–0.053No (discontinued development) 203, 204, 222
ArtesunateNoneSemisynthetic derivative of artemisininSp1/NF-κB activation pathwaysc 3.8Yes (approved for malaria) 212, 213
  • a No drug is officially approved for use on HHV-6.

  • b EC50, 50% effective dose (range or unique value, according to the data in referenced studies).

  • c Cellular component target.